Triple therapy for COPD

Canadian Coordinating Office for Health Technology Assessment
Record ID 32006000026
English, French
Authors' objectives:

The aim of this study was to summarize the available information on adding combination therapy -- with an inhaled corticosteroid and a long-acting beta-adrenergic receptor agonist -- to chronic therapy with tiotropium in patients with stable COPD (chronic obstructive pulmonary disease) [Tiotropium bromide (Spiriva); fluticasone propionate/salmeterol xinafoate (Advair); budesonide/formoterol fumarate Symbicort].

Authors' recommendations: The analysis done in the SPRUCE (SPiRiva Usual CarE) trial suggests that a benefit may be gained by adding tiotropium to combined inhaled corticosteroid and long-acting beta-adrenergic receptor agonist therapy in patients with COPD. However, evidence will need to be provided by the Canadian Optimal Therapy of COPD Trial, which was designed to evaluate this drug combination, before definite conclusions can be drawn about the potential benefit of triple therapy in this population. It will be important to see the impact that this treatment regimen has on clinically meaningful outcomes, such as the frequency of exacerbations and the number of hospital visits, and to see if these correlate with changes in spirometric measures.
Authors' methods: Overview
Project Status: Completed
URL for project:
Year Published: 2005
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Adrenal Cortex Hormones
  • Adrenergic beta-Agonists
  • Budesonide
  • Drug Therapy, Combination
  • Pulmonary Disease, Chronic Obstructive
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.